冠心病,基因变异 z-bo 2020-09-22 337

　　Coronary heart disease is one of the leading causes of modern human death. According to a survey by the World Health Organization, China has the second highest number of deaths from coronary heart disease each year. The onset of coronary heart disease is attributed to atherosclerosis of the coronary arteries of the heart, which leads to narrowing or occlusion of the vascular lumen, which leads to hypoxia, ischemia or necrosis of the myocardium. Cause Hyperlipidemia is the main cause of atherosclerosis. When it comes to blood lipids, everyone may have heard of ingredients such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (triglycerides). Among them, LDL is often referred to as "bad" lipoprotein and is associated with an increased risk of coronary heart disease; HDL can reduce the risk of coronary heart disease. Good "lipoprotein. In addition, are other lipoprotein components of blood lipids related to the development of coronary heart disease?

　　A few days ago, Icelandic researchers used the "genome-wide association study" to analyze the genome sequence of Icelanders. They hope to learn more about the role of various components of blood lipids in the development of atherosclerosis by discovering rare genetic mutations that affect the composition of blood lipids. The research was published in the journal Nature Genetics, a biotechnology company based in Iceland. Researchers at deCODEgeneics analyzed the genome sequence of approximately 120,000 Icelanders and affected a variety of blood lipids. We have discovered 13 rare genetic variants. The component content has a greater impact. Among them, five rare variants of PCSK9, APOA1, ANGPTL4 and LDLR genes are related to the risk of coronary heart disease.

　　Researchers At the same time, the researchers found that the non-HDL cholesterol in blood lipids (ie total cholesterol minus HDL cholesterol) is highly correlated with the risk of coronary heart disease, and it is pure LDL cholesterol. Many people also find that it has a stronger correlation with coronary heart disease risk. In addition to non-HDL cholesterol LDL cholesterol, there are intermediate density lipoprotein (IDL), ultra-low density lipoprotein (VLDL), Chilomicron (chilomicron) and lipoprotein residual cholesterol (RemnantCholesterol). Among these ingredients, the content of triglycerides is relatively high. This indicates that in addition to LDL, other components of non-HDL cholesterol may become targets for the treatment of coronary heart disease in the future.

　　DeCODEgeneics was established in 1996. We promise to use the latest technology to collect DNA and medical data, and build a huge database to find genetic mutations related to diseases. The company collected DNA and medical information from more than 160,000 volunteers in more than half of Iceland's population. In addition, deCODE has a certain relationship with WuXi AppTec, and its derivative company NextCODE has become a member of WuXi AppTec Group-WuXiextCODE. Dr. Kari Stefansson, founder and CEO of deCODE, said: "This study demonstrates the unique ability of gene sequencing to provide new methods for diagnosis, treatment and prevention of diseases."